Genetically encoded biosensors in microbes for Tumor targeting.
The inadequate accuracy of tumor-targeting represents a critical bottleneck in the development of cancer therapies.
APA
Chen X, Zhou Y, et al. (2026). Genetically encoded biosensors in microbes for Tumor targeting.. Biosensors & bioelectronics, 295, 118244. https://doi.org/10.1016/j.bios.2025.118244
MLA
Chen X, et al.. "Genetically encoded biosensors in microbes for Tumor targeting.." Biosensors & bioelectronics, vol. 295, 2026, pp. 118244.
PMID
41317653
Abstract
The inadequate accuracy of tumor-targeting represents a critical bottleneck in the development of cancer therapies. Tumor-specific chemical and environmental cues that differentiate malignant from somatic tissues offer promising opportunities for precise tumor identification. Genetically encoded biosensors enable autonomous sensing and response to tumor biomarkers, and their exceptional programmability allows for enhanced targeting accuracy. This review depicted tumorigenesis and associated biomarkers, including environmental, metabolic, immune and genetic signals. It also cataloged the expanding repertoire of biosensors for tumor-specific biomarker sensing. Furthermore, it details their applications in cancer detection, precision therapy, and disease recording. Finally, it discussed key challenges and future directions for clinical translation. This review provided theoretical guidance for designing genetically encoded biosensors and advancing them into clinical use in cancers.
MeSH Terms
Biosensing Techniques; Neoplasms; Humans; Biomarkers, Tumor; Animals
같은 제1저자의 인용 많은 논문 (5)
- Rare fusion transcript in a refractory adult T-cell lymphoblastic lymphoma.
- Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
- Development of a chemiluminescence immunoassay for proGRP in human serum.
- Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.
- TCF3::HLF-positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort.